Common TitleMK-1439A-028
Official Title Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.
Phase Phase IIB
ClinicalTrials.gov NCT02652260
Treatments
Doravirine
, Doravirine
Tradename:PifeltroOther Names:DORClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)Doravirine-Tenofovir DF-Lamivudine
Doravirine-Tenofovir DF-Lamivudine
Tradename:DelstrigoOther Names:DOR-TDF-3TC, Doravirine-Tenofovir disoproxil fumarate-LamivudineClass:Single-Tablet RegimensFunding
IndustryMerck